<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682796</url>
  </required_header>
  <id_info>
    <org_study_id>TRPH-222-100</org_study_id>
    <nct_id>NCT03682796</nct_id>
  </id_info>
  <brief_title>Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma</brief_title>
  <official_title>Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Triphase Research and Development III Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Triphase Research and Development III Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with
      relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages:
      Dose-Escalation, Dose-Expansion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>21 days</time_frame>
    <description>To determine the MTD of TRPH-222</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate incidence and severity of AEs, serious AEs, TRPH-222-related AEs, AEs leading to death or discontinuation from treatment</measure>
    <time_frame>Up to 28 days after last dose of study drug</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Activity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assess tumor response - ORR for each NHL subtype using Lugano criteria, PFS from first dose to disease progression, OS from first dose to death, DOR for each NHL subtype assessed by Lugano</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPH-222 Pharmacokinetics (PK)</measure>
    <time_frame>Each Cycle is 21 days. Days 1, 8, 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 3; Day 1 of every third cycle thereafter; up to Day 28 after last dose of study drug; Day 60 after last dose of study drug</time_frame>
    <description>Maximum concentration of TRPH-222 (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPH-222 Pharmacokinetics (PK)</measure>
    <time_frame>Each Cycle is 21 days. Days 1, 8, 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 3; Day 1 of every third cycle thereafter; up to Day 28 after last dose of study drug; Day 60 after last dose of study drug</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPH-222 Pharmacokinetics (PK)</measure>
    <time_frame>Each Cycle is 21 days. Days 1, 8, 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 3; Day 1 of every third cycle thereafter; up to Day 28 after last dose of study drug; Day 60 after last dose of study drug</time_frame>
    <description>Half-life (t 1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPH-222 Pharmacokinetics (PK)</measure>
    <time_frame>Each Cycle is 21 days. Days 1, 8, 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 3; Day 1 of every third cycle thereafter; up to Day 28 after last dose of study drug; Day 60 after last dose of study drug</time_frame>
    <description>Exposure (area under the curve; AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPH-222 Pharmacokinetics (PK)</measure>
    <time_frame>Each Cycle is 21 days. Days 1, 8, 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 3; Day 1 of every third cycle thereafter; up to Day 28 after last dose of study drug; Day 60 after last dose of study drug</time_frame>
    <description>Total body clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPH-222 Pharmacokinetics (PK)</measure>
    <time_frame>Each Cycle is 21 days. Days 1, 8, 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 3; Day 1 of every third cycle thereafter; up to Day 28 after last dose of study drug; Day 60 after last dose of study drug</time_frame>
    <description>Volume of distribution (Vd)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma, Mantle-Cell</condition>
  <condition>Lymphoma, Marginal Zone</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Lymphoma, Follicular</condition>
  <arm_group>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated to be &lt;31 subjects across multiple centers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated to be &lt;121 subjects across multiple centers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRPH-222</intervention_name>
    <description>administered by IV, 21-day Cycle</description>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_label>Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age ≥ 18 years at the time of signing the informed consent

          -  Histologically confirmed (2016 WHO lymphoma classification) B-cell NHL that is DLBCL,
             FL (including transformed FL), MZL, or MCL

          -  Relapsed and/or refractory NHL requiring systemic therapy and have failed, are
             intolerant to, or are considered ineligible for standard of care anticancer treatments
             that are known to be potentially curative. Subjects must not be current candidates for
             HSCT. Participants who refuse standard treatments may also be considered provided that
             documentation is provided that the subject has been made aware of all therapeutic
             options

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

        Exclusion Criteria

          -  Presence of a leukemic phase of the lymphoma

          -  &quot;Double hit&quot; or &quot;triple hit&quot; germinal center B cell lymphoma

          -  Previous solid organ allograft (except for corneal transplant)

          -  Peripheral neuropathy &gt; NCI-CTCAE Grade 1

          -  Significant organ dysfunction that would preclude study participation

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias

          -  Any other serious active disease or co-morbid medical condition, according to the
             Investigator's decision or Medical Monitor, that will substantially increase the risk
             associated with the subject's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Precision for Medicine</last_name>
    <phone>858-295-4326</phone>
    <email>Triphase_TRPH-222-100_Inquiries@precisionformedicine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Standford, RN</last_name>
      <phone>480-256-5462</phone>
      <email>Amanda.Stanford@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Javier Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ceonne Kim</last_name>
      <phone>858-822-0201</phone>
      <email>cek008@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Natalie Galanina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damayanti Bhavsar</last_name>
      <phone>732-235-6008</phone>
      <email>bhavsadm@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Rajat Bannerji, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Nichols</last_name>
      <phone>716-845-4359</phone>
      <email>jenna.nichols@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Francisco J. Hernandez-Ilizaliturri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemakatha Rao</last_name>
      <phone>614-685-1976</phone>
      <email>hemalatha.rao@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Beth Christian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael McNicholas, RN</last_name>
      <email>Michael.McNicholas@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tanya Latorre, RN</last_name>
      <email>Tanya.Latorre@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel J. Landsburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-339-4214</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Ian Flinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashvi Patel</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>3190</phone_ext>
      <email>rashvi.patel@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>John Kuruvilla, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadi Zakaria, PhD</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>28326</phone_ext>
      <email>chadi.zakaria.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Sarit Assouline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>ADC</keyword>
  <keyword>CD22</keyword>
  <keyword>SMARTag™ technology</keyword>
  <keyword>TRPH-222</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

